Hologic to Be Acquired by Blackstone and TPG for Up to $79 Per Share
Key Insights
Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash, plus a non-tradable contingent value right (CVR) to receive up to $3 per share based on the achievement of certain global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.
The purchase price represents a premium of approximately 46% to Hologic’s closing price on May 23, 2025, before media reports of a possible transaction.
The transaction includes significant minority investments from ADIA and GIC.
Stephen P. MacMillan, Hologic’s Chairman, President, and CEO, views this as an exciting new chapter, leveraging Blackstone and TPG's resources and expertise to enhance the company's ability to deliver critical medical technologies.
Why this matters: This acquisition could lead to further innovation and expansion in women's health technologies, potentially improving healthcare outcomes globally. The financial backing and expertise of Blackstone and TPG may drive Hologic to develop next-generation solutions and expand its market reach.
In-Depth Analysis
The acquisition is structured such that Hologic stockholders will receive $76 per share in cash, along with a contingent value right (CVR) that could add up to $3 per share. These CVR payments are tied to Hologic’s Breast Health business achieving specific revenue targets in fiscal years 2026 and 2027.
This deal is expected to close in the first half of calendar year 2026, pending Hologic’s stockholders' approval, regulatory approvals, and other customary closing conditions. Upon completion, Hologic’s common stock will be delisted from the Nasdaq stock market, though the company will maintain its headquarters in Marlborough, Massachusetts, and continue to operate under the Hologic name.
The merger agreement also includes a 45-day 'go-shop' period, allowing Hologic to solicit alternative acquisition proposals. Goldman Sachs & Co. LLC is serving as the financial advisor to Hologic, while Citi is advising the Blackstone-and-TPG consortium.
FAQs
Q: What does the acquisition mean for Hologic stockholders?
Hologic stockholders will receive $76 per share in cash, plus a contingent value right of up to $3 per share based on revenue milestones.
Q: When is the acquisition expected to close?
The transaction is expected to close in the first half of calendar year 2026, subject to stockholder and regulatory approvals.
Q: Will Hologic continue to operate under the same name?
Yes, Hologic will maintain its headquarters and continue to operate under the Hologic name and brand.
Key Takeaways
Hologic is being acquired by Blackstone and TPG for up to $79 per share.
The acquisition aims to strengthen Hologic's position in women’s health and accelerate growth.
Stockholders will receive $76 per share plus a contingent value right tied to future revenue milestones.
Discussion
What are your thoughts on the potential impact of this acquisition on the future of women's health technologies? Share this article with others who need to stay ahead of this trend!
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer